Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Brian Taylor SlingsbyDirector | Mineralys TherapeuticsMLYS | Open-market sale | 09/22 | 09/24 | 104,320 sh | $28.81 | $3,005,302.72 | −1.3% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 06/30 | 06/30 | 75,000 sh2 trades | $26.14avg. | $1,960,460 | −10.9% | |
Warren EricChief Commercial Officer | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 06/26 | 06/30 | 104,124 sh | $25.90 | $2,696,811.6 | −73.1% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 06/15–06/17 | 06/17 | 14,474 sh2 trades | $24.19avg. | $350,080.9 | −20.2% | |
Daphne KarydasDirector | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 06/17 | 06/17 | 3,000 sh | $25.00 | $75,000 | −32.6% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 06/10–06/12 | 06/12 | 8,519 sh2 trades | $24.20avg. | $206,181.57 | −11.8% | |
David Malcom RodmanChief Medical Officer | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 05/18 | 05/19 | 417 sh | $27.55 | $11,488.35 | −0.7% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 05/11–05/13 | 05/13 | 22,575 sh3 trades | $28.91avg. | $652,598.17 | −26.2% | |
David Malcom RodmanChief Medical Officer | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 04/17 | 04/21 | 416 sh | $31.33 | $13,033.28 | −0.6% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 04/13–04/15 | 04/15 | 20,406 sh2 trades | $26.89avg. | $548,685 | −22.6% | |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 04/13 | 04/15 | 15,730 sh | $26.83 | $422,035.9 | −2.2% | |
David Malcom RodmanChief Medical Officer | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 04/09 | 04/13 | 2,170 sh | $27.38 | $59,414.6 | −2.8% |
Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 03/31 | 04/02 | 75,000 sh3 trades | $26.27avg. | $1,970,592.47 | −9.6% | |
Daphne KarydasDirector | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 03/31 | 04/02 | 3,000 sh | $25.00 | $75,000 | −32.6% |
Mineralys TherapeuticsMLYS | Open-market buy | 03/27–03/30 | 03/31 | 369,000 sh2 trades | $23.75avg. | $8,762,797 | +6.8% | |
Director | Mineralys TherapeuticsMLYS | Open-market buy | 03/27–03/30 | 03/31 | 369,000 sh2 trades | $23.75avg. | $8,762,797 | +6.8% |
Mineralys TherapeuticsMLYS | Open-market buy | 03/27–03/30 | 03/31 | 369,000 sh2 trades | $23.75avg. | $8,762,797 | +6.8% | |
Mineralys TherapeuticsMLYS | Open-market buy | 03/27–03/30 | 03/31 | 369,000 sh2 trades | $23.75avg. | $8,762,797 | +6.8% | |
Mineralys TherapeuticsMLYS | Open-market buy | 03/27–03/30 | 03/31 | 369,000 sh2 trades | $23.75avg. | $8,762,797 | +6.8% | |
David Malcom RodmanChief Medical Officer | Mineralys TherapeuticsMLYS | Open-market sale10b5-1 plan | 03/17 | 03/17 | 417 sh | $25.65 | $10,696.05 | −0.5% |
